Ciphergen and bioMerieux in Biomarker Collaboration
By Biotechdaily staff writers
Posted on 18 Jul 2003
A collaboration to discover biomarkers and multi-biomarker panels that may improve the diagnosis and management of colon cancer has been announced by bioMerieux S.A. (Marcy-l'Etoile, France) and Ciphergen Biosystems, Inc. (Fremont, CA, USA). Posted on 18 Jul 2003
Using Ciphergen's ProteinChip technology, the two companies will work together on the project. ProteinChip systems enable protein discovery, profiling, characterization, and assay development to provide researchers with predictive analysis capabilities and a better understanding of biologic functions at the protein level. bioMerieux develops and manufactures reagents and automated instruments for medical analyses and product quality control.
"We're delighted that bioMerieux is embracing our ProteinChip technology and calling on Ciphergen's Biomarker Discovery Center's expertise to co-develop potential diagnostic tests for colon cancer,” said William E. Rich, president and CEO of Ciphergen. "Early detection and better classification of this disease would improve chances for cure and impact patient management.”
Related Links:
BioMerieux
Ciphergen
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
